News | July 22, 2023
Lupin launches Luforbec 100/6 for adult asthma and COPD treatment in Germany
Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals
Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
KEYTRUDA plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus concurrent chemoradiotherapy alone in these patients
CMOs showed an increasing reluctance to take on debt in 2022
This transformation will enable GE HealthCare to build a strong foundation for business growth
Shivalik Rasayan Limited has issued LOA to Medicamen Biotech to use its DMF grade Bortezomib API for formulation of Bortezomib injection 3.5mg/ vial
The agreement extends the customer's suite of cloud DevOps, data engineering, and data platform management solutions
Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two additional preclinical programs for other neuroscience indications
First of its kind screening for Glaucoma at grass root level over 10k screened already
Subscribe To Our Newsletter & Stay Updated
